2 hours ago
Moderna (MRNA) Stock Skyrockets 177% on Melanoma Vaccine Breakthrough – Can It Last?
Moderna (MRNA) stock exploded 177% on melanoma vaccine trial success, marking the biggest S&P 500 gain in 20+ years. Analysts question if it's sustainable.
The post Moderna (MRNA) Stock Skyrockets 177% on Melanoma Vaccine Breakthrough – Can It Last? appeared first on Blockonomi.
Source: Blockonomi →Related News
- 40 minutes ago
UPS (UPS) Stock: Inside the $2 Billion Global Expansion Targeting Healthcare
- 47 minutes ago
Stock Futures Decline Monday: Trade Tensions, Iran Sanctions, and Key Earnings D...
- 53 minutes ago
Why Michael Burry Dumped Alibaba (BABA) for JD.com (JD) Stock
- 1 hour ago
Palo Alto Networks (PANW) Stock Sees Wave of Analyst Upgrades Before Fiscal Q4 R...
- 1 hour ago
IBM (IBM) Unveils Groundbreaking Dual-Architecture Mainframe Chip with Arm Integ...